Parascript Participates in EUSOBI Annual Scientific Meeting

Longmont, CO, Sept. 12, 2017 -- Parascript, the leader in automating the interpretation of meaningful, contextual data from images, announces its upcoming participation in the European Society of Breast Imaging (EUSOBI) Annual Scientific Meeting held from Friday, September 22 through Saturday, September 23, 2017, in Berlin, Germany. EUSOBI provides research and education on the best practices in mammography screening, diagnostic and interventional practice for the radiology community while also offering outreach to patients. The society includes radiologists and professionals from all over the world, who specialize in breast imaging and are coming together to discuss the latest in diagnostic techniques and technological innovation.

“EUSOBI is dedicated to early detection and evaluation of breast disease through its research into advanced imaging technologies, training and certification of radiologists to ensure accurate diagnoses of cancer. Early diagnosis and modern treatment start with breast imaging,” said Gina Dailey, Director of Medical Sales at Parascript. “This is why it’s important that we attend this scientific meeting to hear from leading radiologists and provide our insights into the latest in imaging technology.”

In 2012, EUSOBI began a training program to standardize expertise and diagnosis in breast imaging. Over the past five years, EUSOBI’s European Diploma in Breast Imaging has become a regular qualification for breast imaging professionals across Europe. It focuses on training radiologists in the best techniques for performing and interpreting mammography, ultrasound and MRIs.

Breast imaging has many challenges including patients with dense breasts since dense tissue has been shown to hide tumors and is associated with an increased risk of breast cancer—that can be more aggressive cancer. However, identifying patients at low risk is also important to avoid unnecessary tests because it can be stressful and costly for patients called back for further assessment. Parascript AccuDetect CAD, powered by deep learning, uses multiple independent cancer detection algorithms and a unique patented voting methodology to combine its findings. Comparing the results of the multiple image recognition processes allows for improved sensitivity and reduced false-positive rates.

This is an important differentiator, according to the Director of Radiology at Ashley County Medical Center in Crossett, Arkansas that serves one of the largest counties in the state. “Our radiologists have enjoyed using it because it’s more accurate. Having Parascript software sets us apart from what is going on around us. It lets people know that we are serious about taking care of their health and taking care of their families,” said Ronnie Dillion, Director of Radiology at ACMC. “Parascript has been instrumental in helping us to do that.”

In terms of processing efficiency, AccuDetect CAD processes at 11 seconds per image, the fastest of all available FDA-approved CAD systems. The average CAD system takes 30 seconds or more to process a single image. AccuDetect CAD also supports early, more accurate detection, delivering high performance on dense and extremely dense breasts, according to a clinical study reported in Clinical Imaging (M. Lobbes et al., Clinical Imaging 37 (2013) 283-288).

If your company or you are attending the EUSOBI Annual Scientific Meeting or you’re simply interested in finding out more details about Parascript medical imaging, please contact us directly at [email protected].

About Parascript, LLC

Parascript automates the interpretation of meaningful, contextual data from image and document-based information. Parascript® AccuDetect® Computer-Aided Detection (CAD) software helps radiologists read digital mammograms. Using several complementary algorithms and a patented voting method to achieve high sensitivity and low false-positive rates, AccuDetect identifies areas suspicious for breast cancer for further review. AccuDetect improves the performance of radiologists in discriminating between malignant and nonmalignant cases. Visit Parascript Medical Imaging.

Attachments:

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/545f15e4-610c-4a97-9573-a640e1cf240e

Rebecca Rowe
Parascript
303-381-3122
[email protected]